

# Daniel H Solomon

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/1534155/daniel-h-solomon-publications-by-year.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

243  
papers

12,966  
citations

60  
h-index

109  
g-index

279  
ext. papers

15,632  
ext. citations

5.9  
avg, IF

6.45  
L-index

#	Paper	IF	Citations
243	Factors Associated With 10-Year Declines in Physical Health and Function Among Women During Midlife.. <i>JAMA Network Open</i> , <b>2022</b> , 5, e2142773	10.4	0
242	Rheumatoid arthritis disease activity assessed by patient-reported outcomes and flow cytometry before and after an additional dose of COVID-19 vaccine.. <i>Annals of the Rheumatic Diseases</i> , <b>2022</b> ,	2.4	2
241	Adverse effects related to methotrexate polyglutamate levels: adjudicated results from the cardiovascular inflammation reduction trial. <i>Rheumatology</i> , <b>2021</b> , 60, 2963-2968	3.9	1
240	Exploring patient experiences coping with using multiple medications: a qualitative interview study. <i>BMJ Open</i> , <b>2021</b> , 11, e046860	3	0
239	Acceptability of Vaccines Against Preventable Infections Including Coronavirus Disease 2019 Among Patients With Rheumatic Disease. <i>ACR Open Rheumatology</i> , <b>2021</b> , 4, 3	3.5	0
238	Validation of a Bioassay for Predicting Response to Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , <b>2021</b> , 73, 1086-1087	9.5	
237	Testing the Effects of Disease-Modifying Antirheumatic Drugs on Vascular Inflammation in Rheumatoid Arthritis: Rationale and Design of the TARGET Trial. <i>ACR Open Rheumatology</i> , <b>2021</b> , 3, 371-380	3.5	0
236	Designing a Strategy Trial for the Management of Gout: The Use of a Modified Delphi Panel. <i>ACR Open Rheumatology</i> , <b>2021</b> , 3, 341-348	3.5	1
235	Effect of Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Disease Flares in Patients With Rheumatoid Arthritis in Remission: The ARCTIC REWIND Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2021</b> , 325, 1755-1764	27.4	7
234	Predicting Response to Tocilizumab Monotherapy in Rheumatoid Arthritis: A Real-world Data Analysis Using Machine Learning. <i>Journal of Rheumatology</i> , <b>2021</b> , 48, 1364-1370	4.1	3
233	Prescription medications for sleep disturbances among midlife women during 2 years of follow-up: a SWAN retrospective cohort study. <i>BMJ Open</i> , <b>2021</b> , 11, e045074	3	
232	Outcomes of a Mobile App to Monitor Patient-Reported Outcomes in Rheumatoid Arthritis: A Randomized Controlled Trial. <i>Arthritis and Rheumatology</i> , <b>2021</b> , 73, 1421-1429	9.5	5
231	Patient adherence with a smartphone app for patient-reported outcomes in rheumatoid arthritis. <i>Rheumatology</i> , <b>2021</b> , 60, 108-112	3.9	11
230	Classifying Pseudogout Using Machine Learning Approaches With Electronic Health Record Data. <i>Arthritis Care and Research</i> , <b>2021</b> , 73, 442-448	4.7	3
229	Treat-to-Target Approach in Rheumatoid Arthritis: A Quality Improvement Trial. <i>Arthritis Care and Research</i> , <b>2021</b> , 73, 207-214	4.7	4
228	The sequence of disease-modifying anti-rheumatic drugs: pathways to and predictors of tocilizumab monotherapy. <i>Arthritis Research and Therapy</i> , <b>2021</b> , 23, 26	5.7	0
227	Effect of Low-Dose Methotrexate on eGFR and Kidney Adverse Events: A Randomized Clinical Trial. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2021</b> ,	12.7	1

226	Cardiovascular disease risk in calcium pyrophosphate deposition disease: A nationwide study of veterans. <i>Arthritis Care and Research</i> , <b>2021</b> ,	4.7	1
225	Medications for gout and its comorbidities: mutual benefits?. <i>Current Opinion in Rheumatology</i> , <b>2021</b> , 33, 145-154	5.3	1
224	Improving rheumatoid arthritis comparative effectiveness research through causal inference principles: systematic review using a target trial emulation framework. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 883-890	2.4	3
223	External Validation of a Risk Score for Major Toxicity Among Nonsteroidal Anti-Inflammatory Drug Users: Real-World Application. <i>ACR Open Rheumatology</i> , <b>2020</b> , 2, 269-275	3.5	
222	Comparison of a new 3-item self-reported measure of adherence to medication with pharmacy claims data in patients with cardiometabolic disease. <i>American Heart Journal</i> , <b>2020</b> , 228, 36-43	4.9	6
221	Physician Prescribing Patterns and Risk of Future Long-Term Opioid Use Among Patients With Rheumatoid Arthritis: A Prospective Observational Cohort Study. <i>Arthritis and Rheumatology</i> , <b>2020</b> , 72, 1082-1090	9.5	4
220	Education and Professional Development in Rheumatology: Translating Quality Improvement and Education to Clinical Practice. <i>Rheumatic Disease Clinics of North America</i> , <b>2020</b> , 46, 155-166	2.4	
219	Predicting Remission Among Patients With Rheumatoid Arthritis Starting Tocilizumab Monotherapy: Model Derivation and Remission Score Development. <i>ACR Open Rheumatology</i> , <b>2020</b> , 2, 65-73	3.5	2
218	Atrial Fibrillation/flutter Hospitalizations among US Medicaid Recipients with and without Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , <b>2020</b> , 47, 1359-1365	4.1	6
217	Acute Calcium Pyrophosphate Crystal Arthritis Flare Rate and Risk Factors for Recurrence. <i>Journal of Rheumatology</i> , <b>2020</b> , 47, 1261-1266	4.1	4
216	Reply to Letter to the Editor: "Comparison of Teriparatide and Denosumab in Patients Switching from Long-Term Bisphosphonate Use". <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2020</b> , 105,	5.6	
215	A prospective study of dual-energy CT scanning, US and X-ray in acute calcium pyrophosphate crystal arthritis. <i>Rheumatology</i> , <b>2020</b> , 59, 900-903	3.9	14
214	Comment on: Comorbidity burden in axial spondyloarthritis: a cluster analysis: reply. <i>Rheumatology</i> , <b>2020</b> , 59, 692-693	3.9	3
213	Delayed Denosumab Injections and Bone Mineral Density Response: An Electronic Health Record-based Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2020</b> , 105,	5.6	12
212	Reply. <i>Arthritis and Rheumatology</i> , <b>2020</b> , 72, 1407-1408	9.5	
211	Adverse Effects of Low-Dose Methotrexate in a Randomized Double-Blind Placebo-Controlled Trial: Adjudicated Hematologic and Skin Cancer Outcomes in the Cardiovascular Inflammation Reduction Trial. <i>ACR Open Rheumatology</i> , <b>2020</b> , 2, 697-704	3.5	7
210	Effects of Interleukin-1 Inhibition on Incident Hip and Knee Replacement : Exploratory Analyses From a Randomized, Double-Blind, Placebo-Controlled Trial. <i>Annals of Internal Medicine</i> , <b>2020</b> , 173, 509-515	8	39
209	Adverse Effects of Low-Dose Methotrexate. <i>Annals of Internal Medicine</i> , <b>2020</b> , 173, 167	8	1

208	Adverse Effects of Low-Dose Methotrexate: A Randomized Trial. <i>Annals of Internal Medicine</i> , <b>2020</b> , 172, 369-380	8	52
207	Digital health technologies: opportunities and challenges in rheumatology. <i>Nature Reviews Rheumatology</i> , <b>2020</b> , 16, 525-535	8.1	27
206	Comment on: Cytopenias among patients with rheumatic diseases using methotrexate: a meta-analysis of randomized controlled clinical trials: reply. <i>Rheumatology</i> , <b>2020</b> , 59, e76	3.9	
205	Pulmonary Adverse Events in Patients Receiving Low-Dose Methotrexate in the Randomized, Double-Blind, Placebo-Controlled Cardiovascular Inflammation Reduction Trial. <i>Arthritis and Rheumatology</i> , <b>2020</b> , 72, 2065-2071	9.5	11
204	Is race or ethnicity associated with under-utilization of statins among women in the United States: The study of women's health across the nation. <i>Clinical Cardiology</i> , <b>2020</b> , 43, 1388-1397	3.3	3
203	Sleep medications and sleep disturbances across middle aged pre- or peri-menopausal women of different race and ethnicities: A SWAN pharmacoepidemiology cohort study. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2020</b> , 29, 1715-1721	2.6	3
202	Low-Dose Methotrexate and Mucocutaneous Adverse Events: Results of a Systematic Literature Review and Meta-Analysis of Randomized Controlled Trials. <i>Arthritis Care and Research</i> , <b>2020</b> , 72, 1140-1146	4.6	6
201	Incorporating natural language processing to improve classification of axial spondyloarthritis using electronic health records. <i>Rheumatology</i> , <b>2020</b> , 59, 1059-1065	3.9	6
200	Initial disease severity, cardiovascular events and all-cause mortality among patients with systemic lupus erythematosus. <i>Rheumatology</i> , <b>2020</b> , 59, 495-504	3.9	8
199	Cytopenias among patients with rheumatic diseases using methotrexate: a meta-analysis of randomized controlled clinical trials. <i>Rheumatology</i> , <b>2020</b> , 59, 709-717	3.9	10
198	Quality improvement for rheumatoid arthritis care: results from a focus group. <i>Clinical and Experimental Rheumatology</i> , <b>2020</b> , 38, 428-435	2.2	0
197	Association of Geography and Access to Health Care Providers With Long-Term Prescription Opioid Use in Medicare Patients With Severe Osteoarthritis: A Cohort Study. <i>Arthritis and Rheumatology</i> , <b>2019</b> , 71, 712-721	9.5	18
196	Immunosuppressive treatment and the risk of diabetes in rheumatoid arthritis. <i>PLoS ONE</i> , <b>2019</b> , 14, e0210459	3.7	22
195	Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 456-464	2.4	87
194	Predictors of Achieving Remission among Patients with Psoriatic Arthritis Initiating a Tumor Necrosis Factor Inhibitor. <i>Journal of Rheumatology</i> , <b>2019</b> , 46, 475-482	4.1	16
193	Comparison of comorbidities and treatment between ankylosing spondylitis and non-radiographic axial spondyloarthritis in the United States. <i>Rheumatology</i> , <b>2019</b> , 58, 2025-2030	3.9	14
192	Prevalence and predictors for sustained remission in rheumatoid arthritis. <i>PLoS ONE</i> , <b>2019</b> , 14, e0214981	3.7	5
191	Risk of malignancy associated with use of tocilizumab versus other biologics in patients with rheumatoid arthritis: A multi-database cohort study. <i>Seminars in Arthritis and Rheumatism</i> , <b>2019</b> , 49, 222-228	5.3	17

190	Comorbidity burden in axial spondyloarthritis: a cluster analysis. <i>Rheumatology</i> , <b>2019</b> , 58, 1746-1754	3.9	23
189	Temporal increases in 25-hydroxyvitamin D in midlife women: Longitudinal results from the Study of Women's Health Across the Nation. <i>Clinical Endocrinology</i> , <b>2019</b> , 91, 48-57	3.4	3
188	Comparison of Denosumab and Bisphosphonates in Patients With Osteoporosis: A Meta-Analysis of Randomized Controlled Trials. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2019</b> , 104, 1753-1765	5.6	40
187	Derivation and Validation of a Major Toxicity Risk Score Among Nonsteroidal Antiinflammatory Drug Users Based on Data From a Randomized Controlled Trial. <i>Arthritis and Rheumatology</i> , <b>2019</b> , 71, 1225-1231	9.5	9
186	Area-Level Predictors of Medication Nonadherence Among US Medicaid Beneficiaries With Lupus: A Multilevel Study. <i>Arthritis Care and Research</i> , <b>2019</b> , 71, 903-913	4.7	12
185	Gout, Hyperuricemia, and Crystal-Associated Disease Network Consensus Statement Regarding Labels and Definitions for Disease Elements in Gout. <i>Arthritis Care and Research</i> , <b>2019</b> , 71, 427-434	4.7	39
184	Racial/ethnic variation in stroke rates and risks among patients with systemic lupus erythematosus. <i>Seminars in Arthritis and Rheumatism</i> , <b>2019</b> , 48, 840-846	5.3	12
183	Association of Preoperative Opioid Use With Mortality and Short-term Safety Outcomes After Total Knee Replacement. <i>JAMA Network Open</i> , <b>2019</b> , 2, e198061	10.4	32
182	Smoking status and cause-specific discontinuation of tumour necrosis factor inhibitors in axial spondyloarthritis. <i>Arthritis Research and Therapy</i> , <b>2019</b> , 21, 177	5.7	4
181	Blood pressure lowering medication initiation and fracture risk: a SWAN pharmacoepidemiology study. <i>Archives of Osteoporosis</i> , <b>2019</b> , 14, 73	2.9	1
180	Comparison of Teriparatide and Denosumab in Patients Switching From Long-Term Bisphosphonate Use. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2019</b> , 104, 5611-5620	5.6	17
179	Fool Me Twice? The Reemergence of Rofecoxib and the Orphan Drug Act. <i>Annals of Internal Medicine</i> , <b>2019</b> , 171, 578-579	8	
178	Supplementing Claims Data with Electronic Medical Records to Improve Estimation and Classification of Rheumatoid Arthritis Disease Activity: A Machine Learning Approach. <i>ACR Open Rheumatology</i> , <b>2019</b> , 1, 552-559	3.5	4
177	The contribution of obesity to prescription opioid use in the United States. <i>Pain</i> , <b>2019</b> , 160, 2255-2262	8	30
176	Adverse Events and Resource Use Before and After Treat-to-Target in Rheumatoid Arthritis: A Post Hoc Analysis of a Randomized Controlled Trial. <i>Arthritis Care and Research</i> , <b>2019</b> , 71, 1243-1248	4.7	1
175	Chronic Opioid Use in Rheumatoid Arthritis: Prevalence and Predictors. <i>Arthritis and Rheumatology</i> , <b>2019</b> , 71, 670-677	9.5	34
174	Low-Dose Methotrexate for the Prevention of Atherosclerotic Events. <i>New England Journal of Medicine</i> , <b>2019</b> , 380, 752-762	59.2	538
173	Challenges in Implementing Treat-to-Target Strategies in Rheumatology. <i>Rheumatic Disease Clinics of North America</i> , <b>2019</b> , 45, 101-112	2.4	7

172	Azathioprine and Mycophenolate Mofetil Adherence Patterns and Predictors Among Medicaid Beneficiaries With Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , <b>2019</b> , 71, 1419-1424	4.7	14
171	Cardiovascular Risks of Probenecid Versus Allopurinol in Older Patients With Gout. <i>Journal of the American College of Cardiology</i> , <b>2018</b> , 71, 994-1004	15.1	43
170	Impact of Changes in Inflammation on Estimated Ten-Year Cardiovascular Risk in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , <b>2018</b> , 70, 1392-1398	9.5	8
169	No difference in cardiovascular risk of tocilizumab versus abatacept for rheumatoid arthritis: A multi-database cohort study. <i>Seminars in Arthritis and Rheumatism</i> , <b>2018</b> , 48, 399-405	5.3	24
168	The potential benefits of aspirin for primary cardiovascular prevention in rheumatoid arthritis: a secondary analysis of the PRECISION Trial. <i>Rheumatology</i> , <b>2018</b> , 57, 1364-1369	3.9	3
167	Effect of Aspirin Coadministration on the Safety of Celecoxib, Naproxen, and Ibuprofen. <i>Journal of the American College of Cardiology</i> , <b>2018</b> , 71, 1741-1751	15.1	24
166	Pseudogout among Patients Fulfilling a Billing Code Algorithm for Calcium Pyrophosphate Deposition Disease. <i>Rheumatology International</i> , <b>2018</b> , 38, 1083-1088	3.6	4
165	Rheumatoid arthritis. <i>Nature Reviews Disease Primers</i> , <b>2018</b> , 4, 18001	51.1	750
164	Benefits and Sustainability of a Learning Collaborative for Implementation of Treat-to-Target in Rheumatoid Arthritis: Results of a Cluster-Randomized Controlled Phase II Clinical Trial. <i>Arthritis Care and Research</i> , <b>2018</b> , 70, 1551-1556	4.7	8
163	Differences in Safety of Nonsteroidal Antiinflammatory Drugs in Patients With Osteoarthritis and Patients With Rheumatoid Arthritis: A Randomized Clinical Trial. <i>Arthritis and Rheumatology</i> , <b>2018</b> , 70, 537-546	9.5	17
162	Dynamic patterns and predictors of hydroxychloroquine nonadherence among Medicaid beneficiaries with systemic lupus erythematosus. <i>Seminars in Arthritis and Rheumatism</i> , <b>2018</b> , 48, 205-213	5.3	37
161	Medical Care Costs Associated With Rheumatoid Arthritis in the US: A Systematic Literature Review and Meta-Analysis. <i>Arthritis Care and Research</i> , <b>2018</b> , 70, 1431-1438	4.7	25
160	Reply. <i>Arthritis and Rheumatology</i> , <b>2018</b> , 70, 476	9.5	
159	Identification of monosodium urate crystal deposits in patients with asymptomatic hyperuricemia using dual-energy CT. <i>RMD Open</i> , <b>2018</b> , 4, e000593	5.9	22
158	Implementation of Treat-to-Target for Rheumatoid Arthritis in the US: Analysis of Baseline Data From a Randomized Controlled Trial. <i>Arthritis Care and Research</i> , <b>2018</b> , 70, 801-806	4.7	19
157	Outcomes of lupus and rheumatoid arthritis patients with primary dengue infection: A seven-year report from Brazil. <i>Seminars in Arthritis and Rheumatism</i> , <b>2018</b> , 47, 749-755	5.3	5
156	Effect of a Remotely Delivered Tailored Multicomponent Approach to Enhance Medication Taking for Patients With Hyperlipidemia, Hypertension, and Diabetes: The STIC2IT Cluster Randomized Clinical Trial. <i>JAMA Internal Medicine</i> , <b>2018</b> , 178, 1182-1189	11.5	39
155	Use of rheumatology-specific patient navigators to understand and reduce barriers to medication adherence: Analysis of qualitative findings. <i>PLoS ONE</i> , <b>2018</b> , 13, e0200886	3.7	5

154	Association between inflammation and systolic blood pressure in RA compared to patients without RA. <i>Arthritis Research and Therapy</i> , <b>2018</b> , 20, 107	5.7	10
153	Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol: Population-Based Cohort Study. <i>Circulation</i> , <b>2018</b> , 138, 1116-1126	16.7	68
152	Assessment of coronary vascular function with cardiac PET in relation to serum uric acid. <i>PLoS ONE</i> , <b>2018</b> , 13, e0192788	3.7	4
151	Effects of analgesics on bone mineral density: A longitudinal analysis of the prospective SWAN cohort with three-group matching weights. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2018</b> , 27, 182-190	2.6	6
150	Performance of the Expanded Cardiovascular Risk Prediction Score for Rheumatoid Arthritis in a geographically distant National Register-based cohort: an external validation. <i>RMD Open</i> , <b>2018</b> , 4, e000771	5.9	7
149	Asymptomatic hyperuricemia and coronary flow reserve in patients with metabolic syndrome. <i>BMC Rheumatology</i> , <b>2018</b> , 2, 17	2.9	4
148	Barriers to treatment adjustment within a treat to target strategy in rheumatoid arthritis: a secondary analysis of the TRACTION trial. <i>Rheumatology</i> , <b>2018</b> , 57, 1933-1937	3.9	12
147	Relationship of Interleukin-1 Blockade With Incident Gout and Serum Uric Acid Levels: Exploratory Analysis of a Randomized Controlled Trial. <i>Annals of Internal Medicine</i> , <b>2018</b> , 169, 535-542	8	51
146	The clinical status and economic savings associated with remission among patients with rheumatoid arthritis: leveraging linked registry and claims data for synergistic insights. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2017</b> , 26, 310-319	2.6	15
145	Comparison of cardiovascular risk algorithms in patients with vs without rheumatoid arthritis and the role of C-reactive protein in predicting cardiovascular outcomes in rheumatoid arthritis. <i>Rheumatology</i> , <b>2017</b> , 56, 777-786	3.9	24
144	Diet and Rheumatoid Arthritis Symptoms: Survey Results From a Rheumatoid Arthritis Registry. <i>Arthritis Care and Research</i> , <b>2017</b> , 69, 1920-1925	4.7	31
143	Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multi-Database Cohort Study. <i>Arthritis and Rheumatology</i> , <b>2017</b> , 69, 1154-1164	9.5	119
142	Investigating methotrexate toxicity within a randomized double-blinded, placebo-controlled trial: Rationale and design of the Cardiovascular Inflammation Reduction Trial-Adverse Events (CIRT-AE) Study. <i>Seminars in Arthritis and Rheumatism</i> , <b>2017</b> , 47, 133-142	5.3	20
141	Implementation of Treat-to-Target in Rheumatoid Arthritis Through a Learning Collaborative: Results of a Randomized Controlled Trial. <i>Arthritis and Rheumatology</i> , <b>2017</b> , 69, 1374-1380	9.5	30
140	Race/Ethnicity and Cardiovascular Events Among Patients With Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , <b>2017</b> , 69, 1823-1831	9.5	44
139	Pain Severity in Relation to the Final Menstrual Period in a Prospective Multiethnic Observational Cohort: Results From the Study of Women's Health Across the Nation. <i>Journal of Pain</i> , <b>2017</b> , 18, 178-187	5.2	4
138	Comparative Risk of Cardiovascular Outcomes Between Topical and Oral Nonselective NSAIDs in Taiwanese Patients With Rheumatoid Arthritis. <i>Journal of the American Heart Association</i> , <b>2017</b> , 6,	6	11
137	Rationale and Design of the Brigham Cohort for psoriasis and psoriatic arthritis registry (COPPAR). <i>BMC Dermatology</i> , <b>2017</b> , 17, 11	2.1	6

136	The Risk of Major NSAID Toxicity with Celecoxib, Ibuprofen, or Naproxen: A Secondary Analysis of the PRECISION Trial. <i>American Journal of Medicine</i> , <b>2017</b> , 130, 1415-1422.e4	2.4	63
135	Effect of Race and Ethnicity on Antihypertensive Medication Utilization Among Women in the United States: Study of Women's Health Across the Nation (SWAN). <i>Journal of the American Heart Association</i> , <b>2017</b> , 6,	6	5
134	Clinical patient registry recruitment and retention: a survey of patients in two chronic disease registries. <i>BMC Medical Research Methodology</i> , <b>2017</b> , 17, 59	4.7	3
133	Drug safety analyses in a rheumatoid arthritis registry: application of different approaches regarding timing of exposure and confounder measurement. <i>Arthritis Research and Therapy</i> , <b>2017</b> , 19, 130	5.7	2
132	Different Rating of Global Rheumatoid Arthritis Disease Activity in Rheumatoid Arthritis Patients With Multiple Morbidities. <i>Arthritis and Rheumatology</i> , <b>2017</b> , 69, 720-727	9.5	12
131	Goal-Directed Treatment for Osteoporosis: A Progress Report From the ASBMR-NOF Working Group on Goal-Directed Treatment for Osteoporosis. <i>Journal of Bone and Mineral Research</i> , <b>2017</b> , 32, 3-10	6.3	94
130	Gout and the Risk of Non-vertebral Fracture. <i>Journal of Bone and Mineral Research</i> , <b>2017</b> , 32, 230-236	6.3	18
129	Comparative Rates of Serious Infections Among Patients With Systemic Lupus Erythematosus Receiving Immunosuppressive Medications. <i>Arthritis and Rheumatology</i> , <b>2017</b> , 69, 387-397	9.5	46
128	Differential blood pressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis: the PRECISION-ABPM (Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen or Naproxen Ambulatory Blood Pressure Measurement) Trial. <i>European Heart Journal</i> , <b>2017</b> , 38, 3282-3292	9.5	56
127	Low rates of biologic-free clinical disease activity index remission maintenance after biologic disease-modifying anti-rheumatic drug discontinuation while in remission in a Japanese multicentre rheumatoid arthritis registry. <i>Rheumatology</i> , <b>2016</b> , 55, 286-90	3.9	11
126	Risk of incident atrial fibrillation in gout: a cohort study. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 1473-8	3.8	28
125	Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. <i>New England Journal of Medicine</i> , <b>2016</b> , 375, 2519-29	59.2	430
124	Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry. <i>Arthritis Research and Therapy</i> , <b>2016</b> , 18, 280	5.7	17
123	Brief Report: Development and Validation of a Semiautomated Method to Measure Erosion Volume in Inflammatory Arthritis by Computed Tomography Scanning. <i>Arthritis and Rheumatology</i> , <b>2016</b> , 68, 332-6	9.5	4
122	Biologic Disease-Modifying Antirheumatic Drugs and Risk of High-Grade Cervical Dysplasia and Cervical Cancer in Rheumatoid Arthritis: A Cohort Study. <i>Arthritis and Rheumatology</i> , <b>2016</b> , 68, 2106-13	9.5	11
121	The Implications of the Sequestosome 1 Mutation P392L in Patients with Paget's Disease in a United States Cohort. <i>Calcified Tissue International</i> , <b>2016</b> , 98, 489-96	3.9	6
120	Identifying factors associated with concordance with the American College of Rheumatology rheumatoid arthritis treatment recommendations. <i>Arthritis Research and Therapy</i> , <b>2016</b> , 18, 94	5.7	6
119	Impact of the U.S. Food and Drug Administration's Safety-Related Announcements on the Use of Bisphosphonates After Hip Fracture. <i>Journal of Bone and Mineral Research</i> , <b>2016</b> , 31, 1536-40	6.3	76



118	Medication Use by Race and Ethnicity in Women Transitioning Through the Menopause: A Study of Women's Health Across the Nation Drug Epidemiology Study. <i>Journal of Women's Health</i> , <b>2016</b> , 25, 599-605	3.0	1
117	Cardiovascular risk factor management in patients with RA compared to matched non-RA patients. <i>Rheumatology</i> , <b>2016</b> , 55, 809-16	3.9	16
116	Effect of Milnacipran on Pain in Patients with Rheumatoid Arthritis with Widespread Pain: A Randomized Blinded Crossover Trial. <i>Journal of Rheumatology</i> , <b>2016</b> , 43, 38-45	4.1	15
115	Effects of colchicine on risk of cardiovascular events and mortality among patients with gout: a cohort study using electronic medical records linked with Medicare claims. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 1674-9	2.4	82
114	Brief Report: Utilization of the First Biosimilar Infliximab Since Its Approval in South Korea. <i>Arthritis and Rheumatology</i> , <b>2016</b> , 68, 1076-9	9.5	9
113	Traditional Cardiovascular Disease Risk Factor Management in Rheumatoid Arthritis Compared to Matched Nonrheumatoid Arthritis in a US Managed Care Setting. <i>Arthritis Care and Research</i> , <b>2016</b> , 68, 629-37	4.7	13
112	Validation of claims-based algorithms for gout flares. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2016</b> , 25, 820-6	2.6	12
111	Participation in Clinical Research Registries: A Focus Group Study Examining Views From Patients With Arthritis and Other Chronic Illnesses. <i>Arthritis Care and Research</i> , <b>2016</b> , 68, 974-80	4.7	8
110	Potential confounding in colchicine and cardiovascular disease study. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, e27	2.4	1
109	Response to: Effects of colchicine on risk of cardiovascular events among patients with gout: as evidence accrues, is it time for a randomized trial? By Giannopoulos and Deftereos. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, e29	2.4	1
108	Dr. Yoshida, et al reply. <i>Journal of Rheumatology</i> , <b>2016</b> , 43, 1253	4.1	
107	Implementation of treat-to-target in rheumatoid arthritis through a Learning Collaborative: Rationale and design of the TRACTION trial. <i>Seminars in Arthritis and Rheumatism</i> , <b>2016</b> , 46, 81-7	5.3	17
106	Cardiovascular Outcomes Associated with Lowering Low-density Lipoprotein Cholesterol in Rheumatoid Arthritis and Matched Nonrheumatoid Arthritis. <i>Journal of Rheumatology</i> , <b>2016</b> , 43, 1989-1996	4.1	20
105	Alternative Methods for Defining Osteoarthritis and the Impact on Estimating Prevalence in a US Population-Based Survey. <i>Arthritis Care and Research</i> , <b>2016</b> , 68, 574-80	4.7	141
104	Effects of xanthine oxidase inhibitors on cardiovascular disease in patients with gout: a cohort study. <i>American Journal of Medicine</i> , <b>2015</b> , 128, 653.e7-653.e16	2.4	58
103	Subcutaneous nodules are associated with cardiovascular events in patients with rheumatoid arthritis: results from a large US registry. <i>Clinical Rheumatology</i> , <b>2015</b> , 34, 1697-704	3.9	9
102	Development of a multimorbidity index: Impact on quality of life using a rheumatoid arthritis cohort. <i>Seminars in Arthritis and Rheumatism</i> , <b>2015</b> , 45, 167-73	5.3	39
101	Risk of venous thromboembolism in patients with rheumatoid arthritis: initiating disease-modifying antirheumatic drugs. <i>American Journal of Medicine</i> , <b>2015</b> , 128, 539.e7-17	2.4	21

100	Association between lipid levels and major adverse cardiovascular events in rheumatoid arthritis compared to non-rheumatoid arthritis patients. <i>Arthritis and Rheumatology</i> , <b>2015</b> , 67, 2004-10	9.5	38
99	Reductions in Use of Colchicine after FDA Enforcement of Market Exclusivity in a Commercially Insured Population. <i>Journal of General Internal Medicine</i> , <b>2015</b> , 30, 1633-8	4	11
98	An external validation study reporting poor correlation between the claims-based index for rheumatoid arthritis severity and the disease activity score. <i>Arthritis Research and Therapy</i> , <b>2015</b> , 17, 83	5.7	12
97	Statin therapy and risk of fracture: results from the JUPITER randomized clinical trial. <i>JAMA Internal Medicine</i> , <b>2015</b> , 175, 171-7	11.5	42
96	Active-comparator design and new-user design in observational studies. <i>Nature Reviews Rheumatology</i> , <b>2015</b> , 11, 437-41	8.1	125
95	Risk of high-grade cervical dysplasia and cervical cancer in women with systemic inflammatory diseases: a population-based cohort study. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 1360-7	2.4	74
94	Discontinuation of tumour necrosis factor inhibitors in patients with rheumatoid arthritis in low-disease activity: persistent benefits. Data from the Corrona registry. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 1150-5	2.4	34
93	Bone mineral density changes among women initiating proton pump inhibitors or H2 receptor antagonists: a SWAN cohort study. <i>Journal of Bone and Mineral Research</i> , <b>2015</b> , 30, 232-9	6.3	53
92	Dipeptidyl peptidase-4 inhibitors in type 2 diabetes may reduce the risk of autoimmune diseases: a population-based cohort study. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 1968-75	2.4	68
91	Medication Nonadherence Is Associated With Increased Subsequent Acute Care Utilization Among Medicaid Beneficiaries With Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , <b>2015</b> , 67, 1712-21	4.7	68
90	Comparison of Care Provided in Practices With Nurse Practitioners and Physician Assistants Versus Subspecialist Physicians Only: A Cohort Study of Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , <b>2015</b> , 67, 1664-70	4.7	17
89	TRAF1/C5 but not PTPRC variants are potential predictors of rheumatoid arthritis response to anti-tumour necrosis factor therapy. <i>BioMed Research International</i> , <b>2015</b> , 2015, 490295	3	13
88	Treatment Patterns of Multimorbid Patients with Rheumatoid Arthritis: Results from an International Cross-sectional Study. <i>Journal of Rheumatology</i> , <b>2015</b> , 42, 1099-104	4.1	27
87	The impact of multimorbidity status on treatment response in rheumatoid arthritis patients initiating disease-modifying anti-rheumatic drugs. <i>Rheumatology</i> , <b>2015</b> , 54, 2076-84	3.9	36
86	Incidence and Predictors of Biological Antirheumatic Drug Discontinuation Attempts among Patients with Rheumatoid Arthritis in Remission: A CORRONA and NinJa Collaborative Cohort Study. <i>Journal of Rheumatology</i> , <b>2015</b> , 42, 2238-46	4.1	12
85	The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 430-6	2.4	49
84	Bisphosphonates and risk of cardiovascular events: a meta-analysis. <i>PLoS ONE</i> , <b>2015</b> , 10, e0122646	3.7	72
83	Flares in rheumatoid arthritis: frequency and management. A report from the BRASS registry. <i>Journal of Rheumatology</i> , <b>2014</b> , 41, 227-34	4.1	40

82	Multimorbidity and rheumatic conditions-enhancing the concept of comorbidity. <i>Nature Reviews Rheumatology</i> , <b>2014</b> , 10, 252-6	8.1	72
81	Sugar-sweetened soda consumption and risk of developing rheumatoid arthritis in women. <i>American Journal of Clinical Nutrition</i> , <b>2014</b> , 100, 959-67	7	68
80	Rheumatoid arthritis quality measures and radiographic progression. <i>Seminars in Arthritis and Rheumatism</i> , <b>2014</b> , 44, 9-13	5.3	6
79	Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAFETY Assessment of Biologic ThERapy (SABER) study. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 1942-8	2.4	77
78	Linkage of a de-identified United States rheumatoid arthritis registry with administrative data to facilitate comparative effectiveness research. <i>Arthritis Care and Research</i> , <b>2014</b> , 66, 1790-8	4.7	56
77	Inconsistent treatment with disease-modifying antirheumatic drugs: a longitudinal data analysis. <i>Journal of Rheumatology</i> , <b>2014</b> , 41, 2370-8	4.1	9
76	Effect of hydroxychloroquine on insulin sensitivity and lipid parameters in rheumatoid arthritis patients without diabetes mellitus: a randomized, blinded crossover trial. <i>Arthritis Care and Research</i> , <b>2014</b> , 66, 1246-51	4.7	45
75	Review: treat to target in rheumatoid arthritis: fact, fiction, or hypothesis?. <i>Arthritis and Rheumatology</i> , <b>2014</b> , 66, 775-82	9.5	98
74	Roles of nurse practitioners and physician assistants in rheumatology practices in the US. <i>Arthritis Care and Research</i> , <b>2014</b> , 66, 1108-13	4.7	20
73	Predictors of stopping and starting disease-modifying antirheumatic drugs for rheumatoid arthritis. <i>Arthritis Care and Research</i> , <b>2014</b> , 66, 1152-8	4.7	9
72	The potential economic benefits of improved postfracture care: a cost-effectiveness analysis of a fracture liaison service in the US health-care system. <i>Journal of Bone and Mineral Research</i> , <b>2014</b> , 29, 1667-74	6.3	70
71	Osteoporosis medication use after hip fracture in U.S. patients between 2002 and 2011. <i>Journal of Bone and Mineral Research</i> , <b>2014</b> , 29, 1929-37	6.3	208
70	Trends in prescription of opioids from 2003-2009 in persons with knee osteoarthritis. <i>Arthritis Care and Research</i> , <b>2014</b> , 66, 1489-95	4.7	110
69	Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs. <i>Seminars in Arthritis and Rheumatism</i> , <b>2014</b> , 43, 489-97	5.3	74
68	Heart failure risk among patients with rheumatoid arthritis starting a TNF antagonist. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, 1813-8	2.4	43
67	Cardiovascular risk in rheumatoid arthritis: comparing TNF-blockade with nonbiologic DMARDs. <i>American Journal of Medicine</i> , <b>2013</b> , 126, 730.e9-730.e17	2.4	72
66	Unresolved questions in rheumatology: motion for debate: the data support evidence-based management recommendations for cardiovascular disease in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , <b>2013</b> , 65, 1675-83		19
65	Performance of matrix-based risk models for rapid radiographic progression in a cohort of patients with established rheumatoid arthritis. <i>Arthritis Care and Research</i> , <b>2013</b> , 65, 526-33	4.7	25

64	Traditional cardiovascular risk factors, inflammation and cardiovascular risk in rheumatoid arthritis. <i>Rheumatology</i> , <b>2013</b> , 52, 45-52	3.9	121
63	A7.16 Lack of Replication of PTPRC Gene as a Predictor of Response to Anti-Tumour Necrosis Factor Therapy in Patients with Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, A53.2-A53.3	2.4	1
62	Erythropoiesis-stimulating Agent Use among Patients with Lupus Nephritis Approaching End-stage Renal Disease. <i>Journal of Clinical &amp; Cellular Immunology</i> , <b>2013</b> , 4, 179	2.7	4
61	Use of disease-modifying medications for rheumatoid arthritis by race and ethnicity in the National Ambulatory Medical Care Survey. <i>Arthritis Care and Research</i> , <b>2012</b> , 64, 184-9	4.7	46
60	New loop diuretic prescriptions may be an acute risk factor for falls in the nursing home. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2012</b> , 21, 560-3	2.6	31
59	Osteoporosis telephonic intervention to improve medication regimen adherence: a large, pragmatic, randomized controlled trial. <i>Archives of Internal Medicine</i> , <b>2012</b> , 172, 477-83		71
58	Opioid analgesics and the risk of fractures in older adults with arthritis. <i>Journal of the American Geriatrics Society</i> , <b>2011</b> , 59, 430-8	5.6	151
57	Risk of fractures in older adults using antihypertensive medications. <i>Journal of Bone and Mineral Research</i> , <b>2011</b> , 26, 1561-7	6.3	90
56	Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. <i>JAMA - Journal of the American Medical Association</i> , <b>2011</b> , 305, 2525-31	27.4	276
55	Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2011</b> , 70, 576-82	2.4	250
54	Using genetic and clinical data to understand response to disease-modifying anti-rheumatic drug therapy: data from the Brigham and Women's Hospital Rheumatoid Arthritis Sequential Study. <i>Rheumatology</i> , <b>2011</b> , 50, 40-6	3.9	71
53	The comparative safety of analgesics in older adults with arthritis. <i>Archives of Internal Medicine</i> , <b>2010</b> , 170, 1968-76		282
52	The comparative safety of opioids for nonmalignant pain in older adults. <i>Archives of Internal Medicine</i> , <b>2010</b> , 170, 1979-86		172
51	Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity. <i>Annals of the Rheumatic Diseases</i> , <b>2010</b> , 69, 1920-5	2.4	213
50	A cohort study of thiazolidinediones and fractures in older adults with diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2009</b> , 94, 2792-8	5.6	79
49	The relationship between focal erosions and generalized osteoporosis in postmenopausal women with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , <b>2009</b> , 60, 1624-31		50
48	Clinical research in rheumatology: many promises and several disappointments. <i>Current Opinion in Rheumatology</i> , <b>2009</b> , 21, 93-4	5.3	
47	Osteoporosis treatments and adverse events. <i>Current Opinion in Rheumatology</i> , <b>2009</b> , 21, 363-8	5.3	51

46	Development of a health care utilisation data-based index for rheumatoid arthritis severity: a preliminary study. <i>Arthritis Research and Therapy</i> , <b>2008</b> , 10, R95	5.7	49
45	Determining the best treatments for the right people in rheumatology. <i>Current Opinion in Rheumatology</i> , <b>2008</b> , 20, 121-2	5.3	
44	The risk of infection associated with tumor necrosis factor alpha antagonists: making sense of epidemiologic evidence. <i>Arthritis and Rheumatism</i> , <b>2008</b> , 58, 919-28		33
43	Subgroup analyses to determine cardiovascular risk associated with nonsteroidal antiinflammatory drugs and coxibs in specific patient groups. <i>Arthritis and Rheumatism</i> , <b>2008</b> , 59, 1097-104		74
42	The comparative safety and effectiveness of TNF-alpha antagonists [corrected]. <i>Journal of Managed Care Pharmacy</i> , <b>2007</b> , 13, S7-18		14
41	Agreement between patient report and medical record review for medications used for rheumatoid arthritis: the accuracy of self-reported medication information in patient registries. <i>Arthritis and Rheumatism</i> , <b>2007</b> , 57, 234-9		24
40	Osteoporosis improvement: a large-scale randomized controlled trial of patient and primary care physician education. <i>Journal of Bone and Mineral Research</i> , <b>2007</b> , 22, 1808-15	6.3	47
39	Improving care of patients at-risk for osteoporosis: a randomized controlled trial. <i>Journal of General Internal Medicine</i> , <b>2007</b> , 22, 362-7	4	64
38	Percutaneous vertebroplasty among low income Medicare beneficiaries. <i>Spine</i> , <b>2007</b> , 32, 2910-4	3.3	4
37	Prescription opioid use among older adults with arthritis or low back pain. <i>Arthritis and Rheumatism</i> , <b>2006</b> , 55, 35-41		47
36	Development of a preliminary index that predicts adverse events after total knee replacement. <i>Arthritis and Rheumatism</i> , <b>2006</b> , 54, 1536-42		25
35	Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk. <i>Arthritis and Rheumatism</i> , <b>2006</b> , 54, 1378-89		151
34	Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis. <i>Arthritis and Rheumatism</i> , <b>2006</b> , 54, 3390-8		74
33	Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , <b>2006</b> , 54, 3790-8		143
32	Osteoporosis management in patients with rheumatoid arthritis: Evidence for improvement. <i>Arthritis and Rheumatism</i> , <b>2006</b> , 55, 873-7		25
31	Instrumental variable analysis of secondary pharmacoepidemiologic data. <i>Epidemiology</i> , <b>2006</b> , 17, 373-4	3.1	26
30	Evaluating short-term drug effects using a physician-specific prescribing preference as an instrumental variable. <i>Epidemiology</i> , <b>2006</b> , 17, 268-75	3.1	269
29	Medication use patterns for osteoporosis: an assessment of guidelines, treatment rates, and quality improvement interventions. <i>Mayo Clinic Proceedings</i> , <b>2005</b> , 80, 194-202	6.4	71

28	Osteoporosis action: design of the healthy bones project trial. <i>Contemporary Clinical Trials</i> , <b>2005</b> , 26, 78-94	2.3	15
27	Lipid levels and bone mineral density. <i>American Journal of Medicine</i> , <b>2005</b> , 118, 1414	2.4	68
26	Selective cyclooxygenase 2 inhibitors and cardiovascular events. <i>Arthritis and Rheumatism</i> , <b>2005</b> , 52, 1968-78		69
25	Statin lipid-lowering drugs and bone mineral density. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2005</b> , 14, 219-26	2.6	37
24	Compliance with osteoporosis medications. <i>Archives of Internal Medicine</i> , <b>2005</b> , 165, 2414-9		239
23	Which patients with knee problems are likely to benefit from nonarthroplasty surgery? Development of a clinical prediction rule. <i>Archives of Internal Medicine</i> , <b>2004</b> , 164, 509-13		7
22	Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. <i>Circulation</i> , <b>2004</b> , 109, 2068-73	16.7	414
21	Relationship between COX-2 specific inhibitors and hypertension. <i>Hypertension</i> , <b>2004</b> , 44, 140-5	8.5	117
20	Multifaceted intervention to improve rheumatologists' management of glucocorticoid-induced osteoporosis: a randomized controlled trial. <i>Arthritis and Rheumatism</i> , <b>2004</b> , 51, 383-7		52
19	Cardiovascular care and cancer screening in female nurses with and without rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , <b>2004</b> , 51, 429-32		20
18	Cardiovascular risk factors in women with and without rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , <b>2004</b> , 50, 3444-9		163
17	Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. <i>American Heart Journal</i> , <b>2004</b> , 148, 99-104	4.9	440
16	Adherence with osteoporosis practice guidelines: a multilevel analysis of patient, physician, and practice setting characteristics. <i>American Journal of Medicine</i> , <b>2004</b> , 117, 919-24	2.4	84
15	Pharmacoepidemiology and rheumatic diseases: 2001-2002. <i>Current Opinion in Rheumatology</i> , <b>2003</b> , 15, 122-6	5.3	6
14	Trends in knee magnetic resonance imaging. <i>Medical Care</i> , <b>2003</b> , 41, 687-92	3.1	26
13	Determinants of selective cyclooxygenase-2 inhibitor prescribing: are patient or physician characteristics more important?. <i>American Journal of Medicine</i> , <b>2003</b> , 115, 715-20	2.4	73
12	Underuse of osteoporosis medications in elderly patients with fractures. <i>American Journal of Medicine</i> , <b>2003</b> , 115, 398-400	2.4	111
11	Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. <i>Circulation</i> , <b>2003</b> , 107, 1303-7	16.7	946

10	The hidden cost of nonselective nonsteroidal antiinflammatory drugs in older patients. <i>Journal of Rheumatology</i> , <b>2003</b> , 30, 792-8	4.1	24
9	Contribution of hospital characteristics to the volume-outcome relationship: dislocation and infection following total hip replacement surgery. <i>Arthritis and Rheumatism</i> , <b>2002</b> , 46, 2436-44		71
8	Evidence-based guidelines for the use of immunologic tests: antinuclear antibody testing. <i>Arthritis and Rheumatism</i> , <b>2002</b> , 47, 434-44		370
7	Management of glucocorticoid-induced osteoporosis in patients with rheumatoid arthritis: rates and predictors of care in an academic rheumatology practice. <i>Arthritis and Rheumatism</i> , <b>2002</b> , 46, 3136-42		104
6	Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. <i>Archives of Internal Medicine</i> , <b>2002</b> , 162, 1099-104		147
5	Which patients with unstable angina or non-Q-wave myocardial infarction should have immediate cardiac catheterization? A clinical decision rule for predicting who will fail medical therapy. <i>Journal of Clinical Epidemiology</i> , <b>2002</b> , 55, 121-8	5.7	9
4	Does self-management education benefit all populations with arthritis? A randomized controlled trial in a primary care physician network. <i>Journal of Rheumatology</i> , <b>2002</b> , 29, 362-8	4.1	65
3	Should postmenopausal women with rheumatoid arthritis who are starting corticosteroid treatment be screened for osteoporosis? A cost-effectiveness analysis. <i>Arthritis and Rheumatism</i> , <b>2000</b> , 43, 1967-75		31
2	Nonoccupational risk factors for carpal tunnel syndrome. <i>Journal of General Internal Medicine</i> , <b>1999</b> , 14, 310-4	4	104
1	Development and validation of a patient satisfaction scale for musculoskeletal care. <i>Arthritis and Rheumatism</i> , <b>1999</b> , 12, 96-100		21